Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-09-27FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approves a supplemental application for Carbamazepine from Torrent Pharmaceuticals Limited.
-
FDA approval · 2011-09-27FDA Approved: RISPERIDONE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for risperidone, granting approval of a generic risperidone product. This is …
-
FDA approval · 2011-09-24FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved Janssen's supplemental application for Risperdal M-TAB (risperidone), adding the M-TAB dosage form to the approved product.…
-
CLINICAL_TRIALS trial_result · 2011-09-16Clinical Trial Update: Interpersonal and Social Rhythm Therapy Enter the Brief Title for Protocol IRB 09-003781> [NA]
A completed Mayo Clinic clinical trial evaluated Interpersonal and Social Rhythm Therapy for individuals with Bipolar Disorder in the depres…
-
FDA approval · 2011-09-13FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, signaling an approved update to the…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-09-13FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, LLC. This action represents a regul…
-
FDA approval · 2011-09-13FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2011-09-02Clinical Trial Update: PHARMO Institute Seroquel Safety Study
A completed PHARMO Institute safety study evaluating Seroquel (quetiapine) across schizophrenia, major depressive disorder, bipolar disorder…
-
FDA approval · 2011-08-26FDA Approved: RISPERIDONE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Risperidone by Torrent Pharmaceuticals Limited, indicating approval of a generic version of the …
-
FDA approval · 2011-08-25FDA Approved: RISPERIDONE — Supplemental Application (Westminster Pharmaceuticals, LLC)
FDA approved Westminster Pharmaceuticals' supplemental application for risperidone, authorizing a generic version of the antipsychotic. The …
-
FDA label_change · 2011-08-24FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA page documents a supplemental application for RISPERDAL M-TAB (risperidone) by Janssen Pharmaceuticals, typically filed to support l…
-
FDA approval · 2011-08-24FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
The FDA approved a supplemental application for risperidone from Janssen Pharmaceuticals, Inc. The approval updates the drug's labeling.
-
FDA approval · 2011-08-24FDA Approved: RISPERIDONE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA's generic risperidone (ANDA201003).
-
FDA approval · 2011-08-22FDA Approved: CARBATROL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for CARBATROL (carbamazepine) filed by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2011-08-16FDA Approved: RISPERIDONE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Risperidone from Torrent Pharmaceuticals Limited, authorizing changes to the approved generic pr…
-
CLINICAL_TRIALS research · 2011-08-16Clinical Trial Update: Genetic Association Study Between GAD1 and Reelin Polymorphisms and GABA/Glutamate MRS in Bipolar Disorder Type 1 and Healthy Controls: SPECGENE PROJECT
This is a genetic association study (SPECGENE PROJECT) investigating GAD1 and Reelin polymorphisms and their relation to GABA and glutamate …
-
CLINICAL_TRIALS trial_result · 2011-08-16Clinical Trial Update: Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study
A clinical trial investigating biomarkers for bipolar disorder, focusing on chaperones and the endoplasmic reticulum stress response (CHAP s…
-
CLINICAL_TRIALS research · 2011-08-16Clinical Trial Update: Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE
This clinical trial update describes a genetic association study (LICAVALGENE) investigating how single nucleotide polymorphisms relate to c…
-
FDA label_change · 2011-08-09FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for SAPHRIS (asenapine) submitted by Allergan to update the product labeling.
-
FDA approval · 2011-08-09FDA Approved: RISPERIDONE — Supplemental Application (Amici Pharma, Inc.)
The FDA approved Amici Pharma, Inc.'s supplemental application for risperidone, authorizing a generic version of the antipsychotic under an …
-
FDA approval · 2011-08-04FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) submitted by GlaxoSmithKline LLC. The action updates the product's ap…
-
FDA approval · 2011-08-04FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL XR (lamotrigine) from GlaxoSmithKline LLC, authorizing changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2011-08-03Clinical Trial Update: Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder
This clinical trial update describes a specialized clozapine clinic for bipolar disorder and schizoaffective disorder. The study status is c…
-
CLINICAL_TRIALS trial_result · 2011-08-03Clinical Trial Update: Transcranial Magnetic Stimulation in Bipolar Depression [Phase 4]
Phase 4 clinical trial update evaluating transcranial magnetic stimulation for bipolar depression.
-
CLINICAL_TRIALS trial_result · 2011-08-01Clinical Trial Update: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 [Phase 1]
Phase 1 single ascending dose study of AZD4451 in bipolar disorder completed to assess safety, tolerability, and pharmacokinetics.